UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DATE FOR FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
KING OF PRUSSIA, Pa., April 10, 2024 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its first quarter ended March 31, 2024, after the market closes on Wednesday, April 24, 2024. There will be a conference call for investors and analysts at 9:00 a.m. Eastern time on Thursday, April 25, 2024.
A live webcast of the call will be available on the company's website at www.uhs.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.
Universal Health Services, Inc. is one of the nation's largest hospital companies, operating through its subsidiaries, acute care hospitals, behavioral health facilities and ambulatory centers located throughout the United States, the United Kingdom, and Puerto Rico.
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...
